BioCentury
ARTICLE | Emerging Company Profile

TRuCs vs. CARs

Why TCR2's TRuCs could beat out CAR T therapies in solid tumors

June 23, 2017 9:34 PM UTC

TCR2 Therapeutics Inc. is creating autologous T cell therapies that it thinks will have greater activity against solid tumors than CAR T therapies, and broader applicability than TCR therapies. The key to the approach is fusing tumor antigen recognition domains to T cell receptors, which retains the receptors’ six intracellular subunits, as well as their natural shut-off mechanism.

The resulting therapeutics are referred to as T cell receptor fusion constructs (TRuCs). Lead candidate TC-210 is slated to enter the clinic in 2018 to treat solid tumors...

BCIQ Company Profiles

TCR2 Therapeutics Inc.

BCIQ Target Profiles

T cell receptor (TCR)